Correlation Between HCW Biologics and Lipella Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both HCW Biologics and Lipella Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining HCW Biologics and Lipella Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between HCW Biologics and Lipella Pharmaceuticals Common, you can compare the effects of market volatilities on HCW Biologics and Lipella Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in HCW Biologics with a short position of Lipella Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of HCW Biologics and Lipella Pharmaceuticals.

Diversification Opportunities for HCW Biologics and Lipella Pharmaceuticals

0.32
  Correlation Coefficient

Weak diversification

The 3 months correlation between HCW and Lipella is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding HCW Biologics and Lipella Pharmaceuticals Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipella Pharmaceuticals and HCW Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on HCW Biologics are associated (or correlated) with Lipella Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipella Pharmaceuticals has no effect on the direction of HCW Biologics i.e., HCW Biologics and Lipella Pharmaceuticals go up and down completely randomly.

Pair Corralation between HCW Biologics and Lipella Pharmaceuticals

Given the investment horizon of 90 days HCW Biologics is expected to generate 1.18 times less return on investment than Lipella Pharmaceuticals. In addition to that, HCW Biologics is 1.32 times more volatile than Lipella Pharmaceuticals Common. It trades about 0.02 of its total potential returns per unit of risk. Lipella Pharmaceuticals Common is currently generating about 0.03 per unit of volatility. If you would invest  315.00  in Lipella Pharmaceuticals Common on December 27, 2024 and sell it today you would lose (43.00) from holding Lipella Pharmaceuticals Common or give up 13.65% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

HCW Biologics  vs.  Lipella Pharmaceuticals Common

 Performance 
       Timeline  
HCW Biologics 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in HCW Biologics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, HCW Biologics sustained solid returns over the last few months and may actually be approaching a breakup point.
Lipella Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Lipella Pharmaceuticals Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Lipella Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

HCW Biologics and Lipella Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with HCW Biologics and Lipella Pharmaceuticals

The main advantage of trading using opposite HCW Biologics and Lipella Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if HCW Biologics position performs unexpectedly, Lipella Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will offset losses from the drop in Lipella Pharmaceuticals' long position.
The idea behind HCW Biologics and Lipella Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk